Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Mapping vascular plasticity during fibrogenesis identifies fibrosis-associated endothelial cells in early-stage liver disease
Christina Gkantsinikoudi, Joshua P. Dignam, Raju Kumar, Elliot Jokl, Meenakshi Rana, Wenhao Li, Maryna Samus, Stephanie Landi, Varinder S. Athwal, Timothy J. Kendall, Antal Rot, Jonathan A. Fallowfield, Karen Piper Hanley, William Alazawi, Neil P. Dufton
Christina Gkantsinikoudi, Joshua P. Dignam, Raju Kumar, Elliot Jokl, Meenakshi Rana, Wenhao Li, Maryna Samus, Stephanie Landi, Varinder S. Athwal, Timothy J. Kendall, Antal Rot, Jonathan A. Fallowfield, Karen Piper Hanley, William Alazawi, Neil P. Dufton
View: Text | PDF
Research Article Hepatology Vascular biology

Mapping vascular plasticity during fibrogenesis identifies fibrosis-associated endothelial cells in early-stage liver disease

  • Text
  • PDF
Abstract

Vascular plasticity is a crucial biological asset enabling our bodies to rapidly adapt to infections and acute inflammation. However, repeated insults during chronic disease can result in these vascular adaptations becoming irreversible, thereby driving disease progression and fibrosis. This study aimed to understand if phenotypic changes in endothelial cell (EC) identity could be indicative of progressive fibrosis and thereby offer diagnostic and therapeutic opportunities for patients with metabolic dysfunction–associated steatotic liver disease (MASLD). We integrated high-resolution imaging and proteomic and transcriptomic analysis, which collectively highlighted a central role for endothelial-mesenchymal transition–induced (EndMT-induced) EC plasticity in the derivation of fibrosis-associated EC (FAEC). We demonstrated that: (a) full-spectrum flow cytometry can provide new opportunities to categorize and phenotype EC subpopulations; (b) 2 distinct EndMT-derived FAEC subpopulations expanded during fibrogenesis (THY1.2+ICAM1+ and TAGLN+MCAM+ EC) that displayed unique immunomodulatory and metabolic phenotypes; (c) TAGLN+ FAEC are a conserved, profibrotic cell type that arose at early stages of MASLD; and (d) increased hepatic expression of TAGLN was significantly associated with detrimental patient outcomes at all stages of liver disease. This study paves the way for the development of FAEC-specific diagnostic and therapeutic approaches to tackle progressive fibrotic disease.

Authors

Christina Gkantsinikoudi, Joshua P. Dignam, Raju Kumar, Elliot Jokl, Meenakshi Rana, Wenhao Li, Maryna Samus, Stephanie Landi, Varinder S. Athwal, Timothy J. Kendall, Antal Rot, Jonathan A. Fallowfield, Karen Piper Hanley, William Alazawi, Neil P. Dufton

×

Figure 6

Phenotyping the characteristics of retained EC subpopulations by FSFC.

Options: View larger image (or click on image) Download as PowerPoint
Phenotyping the characteristics of retained EC subpopulations by FSFC.
(...
(A) UMAP visualization of 5 Retained EC clusters; 4 (turquoise), 5 (light purple), 6 (green), 7 (violet), and 8 (dark purple). (B–F) Quantification of the number of cells in each cluster expressed as number of cells per gram of liver tissue for Cluster 4 (B), Cluster 5 (C), Cluster 6 (D), Cluster 7 (E), and Cluster 8 (F) per treatment group. (G) Contour plots of clusters 4, 5, 6, 7, and 8 for ICAM1 versus LY6A (top panel) and EMCN versus LYVE1 (bottom panel). (H) Histograms of clusters 4, 5, 6, 7, and 8 comparing the MFI of LYVE1, TM, ICAM1, and LY6A in Sham (top panels) and 8w CCl4–treated animals (bottom panels). (I) Schematic summarizing the common and differential traits of Retained EC clusters. For statistical analysis, 1-way ANOVAs with Tukey’s multiple-comparison tests. n = 5 animals/group.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts